ACOR Insider Trading Activity and SEC Form 4 Filings
ACOR insider trading summary
No open-market insider purchases or sales of Acorda Therapeutics, Inc. (ACOR) have been reported on SEC Form 4 in the past 12 months.
Latest ACOR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 17, 2023 | Ron Cohen | President and CEO | Buy | $7K (10,000 @ $0.65) |
| Mar 16, 2023 | Ron Cohen | President and CEO | Buy | $6K (10,156 @ $0.60) |
| Mar 17, 2022 | Ron Cohen | President and CEO | Sell | $4K (2,289 @ $1.70) |
| Dec 2, 2019 | David Lawrence | Chief, Bus. Ops & PAO | Sell | $2K (1,176 @ $1.60) |
| Dec 2, 2019 | Lauren M Sabella | Chief Commercial Officer | Sell | $2K (1,513 @ $1.60) |
| Dec 2, 2019 | Jane Wasman | President, Intl and GC | Sell | $4K (2,227 @ $1.60) |
| Dec 2, 2019 | Ron Cohen | President and CEO | Sell | $8K (4,699 @ $1.60) |
| Feb 22, 2019 | David Lawrence | Chief, Bus. Ops & PAO | Sell | $10K (761 @ $13.18) |
| Feb 22, 2019 | Lauren M Sabella | Chief Commercial Officer | Sell | $10K (761 @ $13.18) |
| Jan 30, 2019 | Scopia Management, Inc. | 10% Owner | Sell | $112K (7,000 @ $16.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.